Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ribomic, Inc. ( (JP:4591) ) has provided an announcement.
Ribomic Inc. has reported its non-consolidated financial results for the nine months ending December 31, 2024, showing a reduction in losses compared to the same period the previous year. The company maintains a strong equity ratio of over 95% and continues to forecast a stable financial outlook for the full year, despite no expected changes in dividends.
More about Ribomic, Inc.
Ribomic Inc. is a company listed on the Tokyo stock exchange, specializing in the pharmaceutical industry. The company focuses on developing innovative therapeutic solutions and operates primarily within the Japanese market.
YTD Price Performance: 9.64%
Average Trading Volume: 1,817,360
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen4.06B
Find detailed analytics on 4591 stock on TipRanks’ Stock Analysis page.